# Halozyme Therapeutics, Inc.: overview

HALO · Nasdaq · CIK 1159036 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/halo.md) · [Financials](/companies/halo/financials.md) · [Filings](/companies/halo/filings.md) · [Insiders](/companies/halo/insiders.md)

Latest reported revenue: [$481.0m](/filings/0001159036-26-000104.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001159036-26-000104).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [290](/filings/0001159036-25-000045.md) | [298 d](/filings/0001159036-26-000024.md) | [265](/filings/0001159036-26-000068.md) | [326](/filings/0001159036-26-000104.md) | [354](/filings/0001159036-25-000045.md) | [452 d](/filings/0001159036-26-000024.md) | [377](/filings/0001159036-26-000068.md) | [481](/filings/0001159036-26-000104.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [56.3%](/filings/0001159036-25-000045.md) | [58.9% d](/filings/0001159036-26-000024.md) | [53.4%](/filings/0001159036-26-000068.md) | [62.2%](/filings/0001159036-26-000104.md) | [61.5%](/filings/0001159036-25-000045.md) | [(20.6%) d](/filings/0001159036-26-000024.md) | [49.0%](/filings/0001159036-26-000068.md) | [59.8%](/filings/0001159036-26-000104.md) |
| Net margin | % | [47.2%](/filings/0001159036-25-000045.md) | [46.0% d](/filings/0001159036-26-000024.md) | [44.6%](/filings/0001159036-26-000068.md) | [50.7%](/filings/0001159036-26-000104.md) | [49.5%](/filings/0001159036-25-000045.md) | [(31.3%) d](/filings/0001159036-26-000024.md) | [39.8%](/filings/0001159036-26-000068.md) | [47.8%](/filings/0001159036-26-000104.md) |
| Diluted EPS | $ per share | [1.05](/filings/0001159036-25-000045.md) | not reported | [0.93](/filings/0001159036-26-000068.md) | [1.33](/filings/0001159036-26-000104.md) | [1.43](/filings/0001159036-25-000045.md) | not reported | [1.22](/filings/0001159036-26-000068.md) | [1.90](/filings/0001159036-26-000104.md) |
| Free cash flow | $m | [114 d](/filings/0001159036-25-000045.md) | [175 d](/filings/0001159036-26-000024.md) | [153](/filings/0001159036-26-000068.md) | [98.1 d](/filings/0001159036-26-000104.md) | [176 d](/filings/0001159036-25-000045.md) | [218 d](/filings/0001159036-26-000024.md) | [176](/filings/0001159036-26-000068.md) | [237 d](/filings/0001159036-26-000104.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [443](/filings/0001159036-24-000008.md) | [660](/filings/0001159036-25-000010.md) | [829](/filings/0001159036-26-000024.md) | [1,015](/filings/0001159036-26-000024.md) | [1,397](/filings/0001159036-26-000024.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [62.2%](/filings/0001159036-24-000008.md) | [40.5%](/filings/0001159036-25-000010.md) | [40.7%](/filings/0001159036-26-000024.md) | [54.3%](/filings/0001159036-26-000024.md) | [33.6%](/filings/0001159036-26-000024.md) |
| Net margin | % | [90.8%](/filings/0001159036-24-000008.md) | [30.6%](/filings/0001159036-25-000010.md) | [34.0%](/filings/0001159036-26-000024.md) | [43.7%](/filings/0001159036-26-000024.md) | [22.7%](/filings/0001159036-26-000024.md) |
| Diluted EPS | $ per share | [2.74](/filings/0001159036-24-000008.md) | [1.44](/filings/0001159036-25-000010.md) | [2.10](/filings/0001159036-26-000024.md) | [3.43](/filings/0001159036-26-000024.md) | [2.56](/filings/0001159036-26-000024.md) |
| Free cash flow | $m | [298](/filings/0001159036-24-000008.md) | [235](/filings/0001159036-25-000010.md) | [373](/filings/0001159036-26-000024.md) | [468](/filings/0001159036-26-000024.md) | [645](/filings/0001159036-26-000024.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/halo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.04bn | 13,271,095 |  | Added +6,042 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $418.8m | 5,351,312 |  | Added +80,094 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $414.8m | 5,299,008 |  | Added +49,802 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $405.4m | 5,179,434 |  | Added +241,580 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $248.7m | 3,177,997 |  | Reduced −834,497 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $221.7m | 2,832,594 |  | Added +270,285 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $216.8m | 2,773,568 |  | Added +89,885 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $214.5m | 2,740,561 |  | Reduced −172,548 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $197.3m | 2,519,951 |  | Added +14,165 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $196.5m | 2,511,050 |  | Reduced −14,925 |

## Recent filings

[All 1,111 filings](/companies/halo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-30 | 20:20 ET | [8-K](/filings/0001159036-26-000128.md) | 5.02 Departure or appointment of officers or directors | 0001159036-26-000128 |
| 2026-09-22 | 20:41 ET | [8-K](/filings/0001193125-26-398015.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-398015 |
| 2026-09-18 | 12:23 ET | [8-K](/filings/0001159036-26-000126.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001159036-26-000126 |
| 2026-09-16 | 20:32 ET | [8-K](/filings/0001159036-26-000121.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001159036-26-000121 |
| 2026-08-18 | 20:04 ET | [8-K](/filings/0001159036-26-000106.md) | 5.02 Departure or appointment of officers or directors | 0001159036-26-000106 |
| 2026-08-06 | 20:11 ET | [10-Q](/filings/0001159036-26-000104.md) | Quarterly report, period 2026-06-30 | 0001159036-26-000104 |
| 2026-08-06 | 20:08 ET | [8-K](/filings/0001159036-26-000103.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001159036-26-000103 |
| 2026-07-02 | 20:10 ET | [8-K](/filings/0001159036-26-000088.md) | 5.02 Departure or appointment of officers or directors | 0001159036-26-000088 |
| 2026-05-11 | 20:09 ET | [10-Q](/filings/0001159036-26-000068.md) | Quarterly report, period 2026-03-31 | 0001159036-26-000068 |
| 2026-05-11 | 20:06 ET | [8-K](/filings/0001159036-26-000067.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001159036-26-000067 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001159036-26-000024.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/daa75a2b-06a7-4791-aa5c-63c2756efcf8)

## About the filer

- CIK: 1159036
- Tickers: HALO
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.